Table 3.
Comparison of clinical characteristics and treatment response between E2A-PBX1 subgroup and gene-negative subgroup
| Characteristics | E2A-PBX1 | Gene-negative | P-value |
|---|---|---|---|
| Age (years) | 0.142 | ||
| <10 | 20 | 197 | |
| >10 | 0 | 26 | |
| Gender | 0.657 | ||
| Boys | 11 | 134 | |
| Girls | 9 | 89 | |
| WBC (×109/L) | 0.280 | ||
| <50 | 16 | 179 | |
| 50–100 | 1 | 29 | |
| >100 | 3 | 15 | |
| Karyotype | 0.035 | ||
| Favorable | 2 | 71 | |
| Intermediate | 16 | 113 | |
| Adverse | 0 | 2 | |
| Steroid response | 0.443 | ||
| Sensitive | 17 | 201 | |
| Resistant | 3 | 22 | |
| BM remission on day 15 | 0.148 | ||
| M1 | 15 | 118 | |
| M2 | 3 | 60 | |
| M3 | 2 | 45 | |
| BM remission on day 33 | 0.606 | ||
| CR | 20 | 211 | |
| NCR | 0 | 12 | |
| MRD level at TP1 | 0.039 | ||
| <10−4 | 13 | 97 | |
| >10−4 | 5 | 111 | |
| MRD level at TP1 | 0.081 | ||
| <10−3 | 17 | 157 | |
| >10−3 | 1 | 51 | |
| MRD level at TP2 | 0.304 | ||
| <10−4 | 12 | 106 | |
| >10−4 | 6 | 90 |
Abbreviations: WBC, white blood cell; BM, bone marrow; MRD, minimal residual disease; TP1, time point 1; TP2, time point 2; CR, complete response; NCR, not complete response.